Concurrently, immune checkpoint inhibitors, particularly PD‐1/PD‐L1 inhibitors, have demonstrated efficacy in restraining tumor progression in subsets of colorectal and head and neck cancer patients with positive PD‐L1 expression.[39] Therefore, we proposed that patients exhibiting dual features—EGFR overexpression and positive PD‐L1 expression—may derive substantial benefit from CMTM6 targeting nanobodies, and the therapeutic efficacy of the CMTM6 nanobody could potentially surpass that of monotherapy with either EGFR or PD‐L1 inhibitors. Here, EGFR is linked to neoplasm.